FIELD: organic chemistry, biochemistry, medicine, pharmacy.
SUBSTANCE: invention describes a compound of the general formula (I) 
or (II) 
wherein R1 represents hydrogen atom; R2 is taken among the group consisting of aryl and heteroaryl; R3 is taken among the group consisting of halogen atom, nitro-, cyano-group, (C1-C6)-alkyl, (C1-C6)-alkoxy-group, trifluoromethyl, trifluoromethoxy-group, -NH2, -NH-(C1-C6)-alkyl and -N-(C1-C6)-alkyl)2; b is a whole number from 0 to 4; R4 is taken independently among the group consisting of halogen atom, hydroxy-, carboxy-, oxo-group, (C1-C6)-alkyl, (C1-C6)-alkoxy-group, (C1-C6)-alkoxycarbonyl, phenyl (wherein phenyl group can be substituted optionally with one-three substitutes taken independently among RD), phenylsulfonyl, heteroaryl (wherein heteroaryl can be substituted optionally with one-three substitutes taken independently among RD), heterocycloalkyl, -NH2, -NHRA, -N-(RA)2, 
wherein each RD is taken independently among halogen atom, hydroxy-, carboxy-, oxo-group, (C1-C4)-alkyl, (C1-C4)-alkylthio, hydroxy-(C1-C4)-alkyl, (C1-C4)-alkoxy-group, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylcarbonyl, trifluoromethyl, trifluoromethoxy-group, -NH2. -NHRA, -N-(RA)2, -C(O)N(RA)2, -SO2N(RA)2, acetylamino-, nitro-, cyano-group, formyl, (C1-C6)-alkylsulfonyl, carboxy-(C1-C6)-alkyl and aralkyl; c = 0; a means a whole number from 0 to 1; Y is taken among the group consisting of a residue -(C1-C)-alkyl, -C(O)-, -(C2-C6)-alkenyl)-carbonyl, -carbonyl-(C1-C6)-alkyl)-, -C(S)-, -C(O)NH-(C1-C6)_alkyl), -C(O)-(C3-C7)-cycloalkyl)- and (C3-C7)-cycloalkyl)-C(O)-; 
represents phenyl;
is taken among the group consisting of phenyl, heteroaryl and cycloalkyl under condition that when R1 represents hydrogen atom, R3 represents hydrogen atom, b = 0, c = 1, Y represents -CH2-, represents phenyl and 
represents phenyl then R2 is not trimethoxyphenyl, and its pharmaceutically acceptable salts. Also, invention describes a pharmaceutical composition designated for inhibition of activity of phosphodiesterase comprising a pharmaceutically acceptable vehicle and compound by cl. 1, method for preparing pharmaceutical composition, methods for treatment of sexual dysfunction by using compound by cl. 1 or pharmaceutical composition, method for increasing the concentration of cGMP in penis tissue and method for treatment of state when inhibition of activity of phosphodiesterase shows the favorable effect. Invention provides preparing novel compounds possessing useful biological properties.
EFFECT: valuable medicinal and biochemical properties of compounds and composition.
17 cl, 7 tbl, 98 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF BETA-CARBOLINE POSSESSING EFFECT OF PHOSPHODIESTERASE INHIBITORS, PHARMACEUTICAL COMPOSITION (VARIANTS), METHOD FOR ITS PREPARING, METHOD FOR INHIBITION OF PHOSPHODIESTERASE EFFECT (VARIANTS) AND METHOD FOR INCREASING CGMP CONCENTRATION | 2001 |
|
RU2271358C2 |
| SUBSTITUTED PYRIMIDINETHIOALKYL OR ALKYLESTER COMPOUNDS AND METHOD OF INHIBITION OF VIRAL REVERSE TRANSCRIPTASE ACTIVITY | 1996 |
|
RU2167155C2 |
| N-HYDROXY-BENZAMIDES FOR TREATING CANCER | 2011 |
|
RU2577861C2 |
| THIENOPYRIMIDNEDIONES, METHODS FOR THEIR PREPARING (VARIANTS) AND PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2294937C9 |
| KINASE INHIBITORS | 2013 |
|
RU2637944C2 |
| SUBSTITUTED DERIVATIVES OF ISOTHIAZOLE-PYRIDONE-AZETIDYL AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS | 1991 |
|
RU2041226C1 |
| SUBSTITUTED PYRAZOLES, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF CATHEPSIN S ACTIVITY | 2001 |
|
RU2278863C2 |
| NOVEL PHOSPHATE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2617682C2 |
| SUBSTITUTED PYRIMIDINES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR N-OXIDES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1992 |
|
RU2113437C1 |
| ESTROGEN RECEPTOR MODULATORS | 2017 |
|
RU2738646C2 |
